Law360, New York (May 11, 2010, 7:19 PM EDT) -- Pfizer Inc. was hit Tuesday with another securities fraud class action over its anti-inflammatory drug Bextra, this time being accused of failing to tell investors it was illegally promoting off-label uses for Bextra and three other drugs and offering kickbacks to doctors to promote the medications.
The lawsuit was filed in the U.S. District Court for the Southern District of New York, according to a statement from Robbins Geller Rudman & Dowd LLP, the firm representing the lead plaintiff.
The complaint alleges Pfizer's directors and officers...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.